Skip to content

Effect of whey protein on weight loss

Effect of whey protein on levels of endocannabinoids, glycemic and lipid profile, inflammatory factors, adipocytokines and body composition in obese women on a weight-loss diet

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017021410181N8
Enrollment
60
Registered
2017-03-10
Start date
2017-04-04
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity. Obesity due to excess calories

Interventions

Intervention 1: control group: will receive standard weight loss (macronutrients percent will be carbohydrate55%, fat 30% and 15% protein). Intervention 2: intervention group: Isocaleric weight loss d
Treatment - Other
control group: will receive standard weight loss (macronutrients percent will be carbohydrate55%, fat 30% and 15% protein).
intervention group: Isocaleric weight loss diet and whey protein powders will be prescribed. Each of intervention group subjects, will receive 30 gram whey protein powders per day.

Sponsors

Ahvaz Jundishapur University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 48 Years

Inclusion criteria

Inclusion criteria: inclusion criteria : aged 18 years and older; BMI range of 30 to 40 kg/m2; absence of menopause; lactation; pregnancy; food allergies; not having cancer, hepatic, renal, thyroid and gastrointestinal disorders; no surgery for weight loss; no weight loss over the past 6 months; no taking herbs and drug that reduce appetite and weight and vitamin-mineral supplements. Exclusion criteria: become pregnant during study; unwilling to continue; no consumption of powders exceed 10% of total administered powders.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Serum Insulin. Timepoint: Before and 2 months after the intervention. Method of measurement: Bloodletting.;Endocannabinoids. Timepoint: Before and 2 months after the intervention. Method of measurement: Bloodletting.;Glucose. Timepoint: Before and 2 months after the intervention. Method of measurement: Bloodletting.;Leptin. Timepoint: Before and 2 months after the intervention. Method of measurement: Bloodletting.;Interluekin-6. Timepoint: Before and 2 months after the intervention. Method of measurement: Bloodletting.;Adiponectin. Timepoint: Before and 2 months after the intervention. Method of measurement: Bloodletting.;TNF-a. Timepoint: Before and 2 months after the intervention. Method of measurement: Bloodletting.;Lipid profile. Timepoint: Before and 2 months after the intervention. Method of measurement: Bloodletting.;Weight. Timepoint: Before and 2 months after the intervention. Method of measurement: Seca scale-kg.;Body Composition. Timepoint: Before and 2 months after the intervention. Method of measurement: Body Composition Analyzer.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVahideh Aghamohammadi

Ahvaz Jundishapur University of Medical Sciences

v_agamohammadi@yahoo.com+98 61 3333 9092

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 8, 2026